Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Targovax ASA ( (GB:0RIS) ) is now available.
Circio Holding ASA and NeoRegen Biotech have announced the signing of a second Material Transfer Agreement to advance their collaboration on circular RNA expression-based therapeutics. This partnership, which has moved to the in vivo preclinical stage, aims to tackle challenges in nucleic acid drug delivery by combining Circio’s circVec platform with NeoRegen’s NICT technology. The collaboration seeks to validate the therapeutic potential of these technologies and identify target disease indications, with implications for advancing gene and cell therapies.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in circular RNA vector expression technology for next-generation nucleic acid medicine, with applications in genetic medicine, cell therapy, and chronic disease. NeoRegen Biotech, based in South Korea, focuses on advanced intracellular delivery technologies, particularly for gene, cell, and RNA-based therapies, using its proprietary NICT platform.
YTD Price Performance: -11.83%
Average Trading Volume: 1,369,240
Current Market Cap: NOK64M
Find detailed analytics on 0RIS stock on TipRanks’ Stock Analysis page.